Deriving a Preference-Based Measure for Myelofibrosis from the EORTC QLQ-C30 and the MF-SAF.

[1]  J. Brazier,et al.  Does the generic cancer outcome measure eortc qlq-c30 work in myelofibrosis? , 2015 .

[2]  S. Paisley,et al.  A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures. , 2014, Health technology assessment.

[3]  J. Brazier,et al.  Economic evaluation in short bowel syndrome (SBS): an algorithm to estimate utility scores for a patient-reported SBS-specific quality of life scale (SBS-QoL™) , 2014, Quality of Life Research.

[4]  J. Brazier,et al.  Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. , 2014, Health technology assessment.

[5]  Xiaolei Zhou,et al.  Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy , 2013, British journal of haematology.

[6]  Kia-Chong Chua,et al.  Development of DEMQOL-U and DEMQOL-PROXY-U: generation of preference-based indices from DEMQOL and DEMQOL-PROXY for use in economic evaluation. , 2013, Health technology assessment.

[7]  M. Drummond,et al.  Using QALYs in Cancer , 2012, PharmacoEconomics.

[8]  M. Barkham,et al.  Developing and testing methods for deriving preference-based measures of health from condition-specific measures (and other patient-based measures of outcome). , 2012, Health technology assessment.

[9]  D. Whalley,et al.  PCN95 Using a Condition-Specific Measure of Patient-Reported Outcomes to Derive Utilities in Myelofibrosis , 2012 .

[10]  Xiaolei Zhou,et al.  Health-related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT-II study. , 2012 .

[11]  G. Baker,et al.  The development of a QALY measure for epilepsy: NEWQOL-6D , 2012, Epilepsy & Behavior.

[12]  Jason Gotlib,et al.  A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. , 2012, The New England journal of medicine.

[13]  Z. Estrov,et al.  Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement , 2011, Cancer.

[14]  Benjamin M Craig,et al.  Deriving a preference-based measure for cancer using the EORTC QLQ-C30. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[15]  Aki Tsuchiya,et al.  A uniform time trade off method for states better and worse than dead: feasibility study of the 'lead time' approach. , 2011, Health economics.

[16]  J. Brazier,et al.  The Use of Rasch Analysis in Reducing a Large Condition-Specific Instrument for Preference Valuation , 2011, Medical decision making.

[17]  M. Drummond,et al.  Using QALYs in Cancer: A Review of the Methdological Limitations , 2010 .

[18]  J. Sloan,et al.  The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. , 2009, Leukemia research.

[19]  J. Brazier,et al.  The first stage of developing preference-based measures: constructing a health-state classification using Rasch analysis , 2009, Quality of Life Research.

[20]  David Cella,et al.  The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation , 2003, Health and quality of life outcomes.

[21]  P. Fayers,et al.  Quality of life research within the EORTC-the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer. , 2002, European journal of cancer.

[22]  Paul Kind,et al.  UK population norms for EQ-5D , 1999 .

[23]  P. Dolan,et al.  Modeling valuations for EuroQol health states. , 1997, Medical care.

[24]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[25]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[26]  J. Brazier,et al.  Outcomes of social care for adults: developing a preference-weighted measure. , 2012, Health technology assessment.

[27]  Julia Earnshaw,et al.  NICE Guide to the Methods of Technology Appraisal , 2012, PharmacoEconomics.

[28]  Andy Field,et al.  Discovering statistics using SPSS, 2nd ed. , 2005 .

[29]  Luigi Tesio,et al.  Measuring behaviours and perceptions: Rasch analysis as a tool for rehabilitation research. , 2003, Journal of rehabilitation medicine.

[30]  Andy P. Field,et al.  Discovering Statistics Using SPSS , 2000 .